New psoriasis ointment shows promise in large chinese trial
NCT ID NCT05919082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new ointment (LEO 90100) against a standard one (Daivobet) for stable plaque psoriasis in 604 Chinese adults. Participants applied the treatment for 4 weeks. The goal was to see if the new ointment could clear or nearly clear psoriasis patches better than the standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STABLE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LEO Pharma Investigational Site
Bengbu, Anhui, 233060, China
-
LEO Pharma Investigational Site
Hefei, Anhui, 230022, China
-
LEO Pharma Investigational Site
Beijing, Beijing Municipality, 100044, China
-
LEO Pharma Investigational Site
Beijing, Beijing Municipality, 100050, China
-
LEO Pharma Investigational Site
Chongqing, Chongqing Municipality, 400021, China
-
LEO Pharma Investigational Site
Chongqing, Chongqing Municipality, 400042, China
-
LEO Pharma Investigational Site
Guangzhou, Guangdong, 510080, China
-
LEO Pharma Investigational Site
Guangzhou, Guangdong, 516006, China
-
LEO Pharma Investigational Site
Shenzhen, Guangdong, 518020, China
-
LEO Pharma Investigational Site
Cangzhou, Hebei, 061000, China
-
LEO Pharma Investigational Site
Chengde, Hebei, 067000, China
-
LEO Pharma Investigational Site
Shijiangzhuang, Hebei, 050030, China
-
LEO Pharma Investigational Site
Nanyang, Henan, 473004, China
-
LEO Pharma Investigational Site
Shiyan, Hubei, 442000, China
-
LEO Pharma Investigational Site
Wuhan, Hubei, 430022, China
-
LEO Pharma Investigational Site
Changsha, Hunan, 410011, China
-
LEO Pharma Investigational Site
Baotou, Inner Mongolia, 014010, China
-
LEO Pharma Investigational Site
Baotou, Inner Mongolia, 014016, China
-
LEO Pharma Investigational Site
Hohhot, Inner Mongolia, 010000, China
-
LEO Pharma Investigational Site
Wuxi, Jiangsu, 214002, China
-
LEO Pharma Investigational Site
Yangzhou, Jiangsu, 225003, China
-
LEO Pharma Investigational Site
Zhenjiang, Jiangsu, 212001, China
-
LEO Pharma Investigational Site
Changchun, Jilin, 130021, China
-
LEO Pharma Investigational Site
Xi'an, Shaanxi, 510080, China
-
LEO Pharma Investigational Site
Dongying, Shandong, 257099, China
-
LEO Pharma Investigational Site
Jinan, Shandong, 250013, China
-
LEO Pharma Investigational Site
Jinan, Shandong, 250022, China
-
LEO Pharma Investigational Site
Shanghai, Shanghai Municipality, 200443, China
-
LEO Pharma Investigational Site
Chengdu, Sichuan, 610044, China
-
LEO Pharma Investigational Site
Suining, Sichuan, 629000, China
-
LEO Pharma Investigational Site
Hangzhou, Zhejiang, 310003, China
-
LEO Pharma Investigational Site
Hangzhou, Zhejiang, 310009, China
-
LEO Pharma Investigational Site
Hangzhou, Zhejiang, 310014, China
-
LEO Pharma Investigational Site
Hangzhou, Zhejiang, 310016, China
-
LEO Pharma Investigational Site
Jiaxing, Zhejiang, 314001, China
-
LEO Pharma Investigational Site
Ningbo, Zhejiang, 315010, China
-
LEO Pharma Investigational Site
Ningbo, Zhejiang, 315016, China
-
LEO Pharma Investigational Site
Wenzhou, Zhejiang, 325000, China